Skip to main content
Top
Published in: Current Cardiology Reports 3/2013

01-03-2013 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent

Authors: Alexandrios Briasoulis, George L. Bakris

Published in: Current Cardiology Reports | Issue 3/2013

Login to get access

Abstract

Chronic kidney disease (CKD) is associated with accelerated cardiovascular disease (CVD) risk and a higher CVD event rate. Substantial data from prospective cohort studies support the concept that dialysis patients as well as those with advanced stage (stages 3–5) CKD are associated with an increased risk for all-cause and cardiovascular mortality. The risk for coronary artery disease (CAD) increases exponentially with declining kidney function, i.e., stage 3 or higher CKD. Indeed, CVD accounts for more than 50 % of deaths in patients with CKD. CKD patients are more likely to die of CVD than to progress to end stage kidney disease. This increase in CV risk is commonly attributed to co-existence of numerous traditional and nontraditional risk factors for the development of CVD that frequently accompany reduced kidney function. Therefore, CKD itself is now considered an independent CVD risk factor and a coronary artery disease (CAD) equivalent for all-cause mortality. All patients at risk for CAD should be evaluated for kidney disease. Treatments used for management of established CAD might have similar benefits for patients with concomitant CKD.
Literature
2.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef
3.
go back to reference •• Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163:399–406. This observational study used record-linked data from the US Renal Data System and Third National Registry of Myocardial Infarction to identify 2390 dialysis patients with myocardial infarction hospitalizations. It concludes that non-dialysis-dependent, advanced CKD patients who have had an acute myocardial infarction are similar to dialysis patients.PubMedCrossRef •• Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163:399–406. This observational study used record-linked data from the US Renal Data System and Third National Registry of Myocardial Infarction to identify 2390 dialysis patients with myocardial infarction hospitalizations. It concludes that non-dialysis-dependent, advanced CKD patients who have had an acute myocardial infarction are similar to dialysis patients.PubMedCrossRef
4.
go back to reference Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.PubMedCrossRef Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.PubMedCrossRef
5.
go back to reference Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–8.PubMedCrossRef Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–8.PubMedCrossRef
6.
go back to reference Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.PubMedCrossRef Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.PubMedCrossRef
7.
go back to reference • van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52. This is a collaborative meta-analysis of 10 cohorts with 266,975 patientsselected because of increased risk for chronic kidney disease, defined as a history of hypertension, diabetes, or cardiovascular disease. It found that an eGFR <45 ml/min/1.73 m 2 or albuminuria >300 mg/day were associated with an increase in all-cause and CV mortality.PubMedCrossRef • van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52. This is a collaborative meta-analysis of 10 cohorts with 266,975 patientsselected because of increased risk for chronic kidney disease, defined as a history of hypertension, diabetes, or cardiovascular disease. It found that an eGFR <45 ml/min/1.73 m 2 or albuminuria >300 mg/day were associated with an increase in all-cause and CV mortality.PubMedCrossRef
8.
go back to reference Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010;8:604–11.PubMedCrossRef Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010;8:604–11.PubMedCrossRef
9.
go back to reference Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.PubMedCrossRef Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.PubMedCrossRef
10.
go back to reference Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMed Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMed
11.
go back to reference •• Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14. This is a population-based cohort with measures of estimated glomerular filtration rate (eGFR) and proteinuria from Alberta, Canada. Over a million people were studied and the results indicate that presence of Stage 3 CKD had a higher all-cause mortality than previous myocardial infarction.PubMedCrossRef •• Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14. This is a population-based cohort with measures of estimated glomerular filtration rate (eGFR) and proteinuria from Alberta, Canada. Over a million people were studied and the results indicate that presence of Stage 3 CKD had a higher all-cause mortality than previous myocardial infarction.PubMedCrossRef
12.
go back to reference Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012;380:783–5.PubMedCrossRef Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012;380:783–5.PubMedCrossRef
13.
go back to reference Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–42.PubMedCrossRef Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–42.PubMedCrossRef
14.
go back to reference Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–23.PubMedCrossRef Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–23.PubMedCrossRef
15.
go back to reference Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol. 2009;29:1277–82.PubMedCrossRef Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol. 2009;29:1277–82.PubMedCrossRef
16.
go back to reference Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008;103:e28–34.PubMedCrossRef Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008;103:e28–34.PubMedCrossRef
17.
go back to reference Nadra I, Boccaccini AR, Philippidis P, Whelan LC, McCarthy GM, Haskard DO, et al. Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis. 2008;196:98–105.PubMedCrossRef Nadra I, Boccaccini AR, Philippidis P, Whelan LC, McCarthy GM, Haskard DO, et al. Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis. 2008;196:98–105.PubMedCrossRef
18.
go back to reference Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004;110:3424–9.PubMedCrossRef Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004;110:3424–9.PubMedCrossRef
19.
go back to reference Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003;14:311–6.PubMedCrossRef Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003;14:311–6.PubMedCrossRef
20.
go back to reference Ishimura E, Shoji T, Emoto M, Motoyama K, Shinohara K, Matsumoto N, et al. Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis. 2001;38:S186–90.PubMedCrossRef Ishimura E, Shoji T, Emoto M, Motoyama K, Shinohara K, Matsumoto N, et al. Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis. 2001;38:S186–90.PubMedCrossRef
21.
go back to reference Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111:c117–26.PubMedCrossRef Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111:c117–26.PubMedCrossRef
22.
go back to reference Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–8.PubMedCrossRef Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–8.PubMedCrossRef
23.
go back to reference Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008;CD007176. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008;CD007176.
24.
go back to reference Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402–10.PubMedCrossRef Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402–10.PubMedCrossRef
25.
go back to reference • Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012;178:100–5. Reviews the difference in lipid profiles and mechanisms that contribute to the differences. It compares lipid profiles of people with advanced CKD as well as dilaysis patients to those with normal kidney function.PubMedCrossRef • Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012;178:100–5. Reviews the difference in lipid profiles and mechanisms that contribute to the differences. It compares lipid profiles of people with advanced CKD as well as dilaysis patients to those with normal kidney function.PubMedCrossRef
26.
go back to reference Bouvet C, Moreau S, Blanchette J, de Blois D, Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28:856–62.PubMedCrossRef Bouvet C, Moreau S, Blanchette J, de Blois D, Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28:856–62.PubMedCrossRef
27.
go back to reference Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol. 2011;300:C210–20.PubMedCrossRef Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol. 2011;300:C210–20.PubMedCrossRef
28.
go back to reference McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122–9.PubMedCrossRef McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122–9.PubMedCrossRef
29.
go back to reference Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011;154:12–21.PubMed Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011;154:12–21.PubMed
30.
go back to reference Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14:2919–25.PubMedCrossRef Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14:2919–25.PubMedCrossRef
31.
go back to reference Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585–92.PubMedCrossRef Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585–92.PubMedCrossRef
32.
go back to reference Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80:1270–7.PubMedCrossRef Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80:1270–7.PubMedCrossRef
33.
go back to reference Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217–24.PubMedCrossRef Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217–24.PubMedCrossRef
34.
go back to reference • Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011;154:310–8. Reviews role eGFR and albuminuria in people with CKD from the ONTARGET study in the context of CV risk.PubMed • Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011;154:310–8. Reviews role eGFR and albuminuria in people with CKD from the ONTARGET study in the context of CV risk.PubMed
35.
go back to reference Wattanakit K, Coresh J, Muntner P, Marsh J, Folsom AR. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol. 2006;48:1183–9.PubMedCrossRef Wattanakit K, Coresh J, Muntner P, Marsh J, Folsom AR. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol. 2006;48:1183–9.PubMedCrossRef
36.
go back to reference Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, Angleman S, et al. Kidney dysfunction and fatal cardiovascular disease—an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J. 2008;155:62–8.PubMedCrossRef Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, Angleman S, et al. Kidney dysfunction and fatal cardiovascular disease—an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J. 2008;155:62–8.PubMedCrossRef
37.
go back to reference •• Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–61. Data from 45 cohorts with 1, 127, 656 participants was analyzed, 364 344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts.PubMedCrossRef •• Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–61. Data from 45 cohorts with 1, 127, 656 participants was analyzed, 364 344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts.PubMedCrossRef
38.
go back to reference •• Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73. Data from 1, 024, 977 participants (128 505 with diabetes) from 30 general population and high-risk cardiovascular cohorts and 13 chronic kidney disease cohorts was analyzed. Those with diabetes and CKD had the highest mortality risk, however, those with CKD had a higher mortality risk than those with diabetes and no CKD.PubMedCrossRef •• Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73. Data from 1, 024, 977 participants (128 505 with diabetes) from 30 general population and high-risk cardiovascular cohorts and 13 chronic kidney disease cohorts was analyzed. Those with diabetes and CKD had the highest mortality risk, however, those with CKD had a higher mortality risk than those with diabetes and no CKD.PubMedCrossRef
39.
go back to reference • Siasos G, Tousoulis D, Michalea S, Oikonomou E, Kolia C, Kioufis S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease. Curr Med Chem. 2012;19:2555–71. This is a nice review of the state of biomarkers in determining CV risk in people with CKD.PubMedCrossRef • Siasos G, Tousoulis D, Michalea S, Oikonomou E, Kolia C, Kioufis S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease. Curr Med Chem. 2012;19:2555–71. This is a nice review of the state of biomarkers in determining CV risk in people with CKD.PubMedCrossRef
40.
go back to reference • Slinin Y, Ishani A, Rector T, Fitzgerald P, Macdonald R, Tacklind J, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI Clinical Practice Guideline. Am J Kidney Dis. 2012;60:747–69. This is a systematic review of studies evalauting glycemic control and lipid lowering in CKD. It demonstrates that glycemic control does not slow nephropathy progression or significantly reduce mortality in CKD while lipid lowering trends toward reducing mortality in CKD.PubMedCrossRef • Slinin Y, Ishani A, Rector T, Fitzgerald P, Macdonald R, Tacklind J, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI Clinical Practice Guideline. Am J Kidney Dis. 2012;60:747–69. This is a systematic review of studies evalauting glycemic control and lipid lowering in CKD. It demonstrates that glycemic control does not slow nephropathy progression or significantly reduce mortality in CKD while lipid lowering trends toward reducing mortality in CKD.PubMedCrossRef
41.
go back to reference Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.PubMedCrossRef Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.PubMedCrossRef
42.
go back to reference Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10:156–61.PubMedCrossRef Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10:156–61.PubMedCrossRef
Metadata
Title
Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent
Authors
Alexandrios Briasoulis
George L. Bakris
Publication date
01-03-2013
Publisher
Current Science Inc.
Published in
Current Cardiology Reports / Issue 3/2013
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-012-0340-4

Other articles of this Issue 3/2013

Current Cardiology Reports 3/2013 Go to the issue

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

PET and SPECT in Heart Failure

Echocardiography (RM Lang, Section Editor)

Interventional Echocardiography in Structural Heart Disease

New Therapies for Cardiovascular Disease (K Mahaffey, Section Editor)

PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics